• Geneticin (G-418 Sulfate): Precision Selection and Antiviral

  2026-05-06

  Discover how G418 Sulfate (Geneticin) revolutionizes genetic engineering selection and antiviral research. This article uniquely explores its ribosomal targeting pathway, advanced assay design, and new insights from resistance studies.

• Dantrolene Sodium Salt: Precision Modulation of DNA Repair a

  2026-05-06

  Explore how Dantrolene sodium salt enables high-fidelity modulation of ryanodine receptor activity and DNA repair pathway choice in advanced genome editing. This article offers a unique, protocol-driven perspective for maximizing assay specificity and translational relevance.

• Halazone: Beyond Disinfection—Molecular Insights and Assay I

  2026-05-05

  Explore Halazone as a powerful antimicrobial sulfonamide derivative with dual roles in water disinfection and neurophysiological research. This article uniquely unpacks the molecular mechanisms and assay-critical insights underpinning Halazone’s broad-spectrum action.

• Deracoxib and Piroxicam Suppress Canine Mammary Tumor Cells

  2026-05-05

  This study evaluated the direct cytotoxic and pro-apoptotic effects of the selective COX-2 inhibitor deracoxib, alone and in combination with piroxicam, on canine mammary carcinoma cells. The results reveal that combined treatment induces greater cell death and cell cycle arrest at lower concentrations than either drug alone, supporting the potential for combination NSAID strategies in canine mammary cancer research.

• E-4031: hERG Potassium Channel Blocker in Cardiac Research

  2026-05-04

  E-4031 stands as the benchmark hERG potassium channel blocker for cardiac electrophysiology research and proarrhythmic substrate modeling. With high purity and reproducibility from APExBIO, it enables precise assessment of QT interval prolongation and arrhythmia risk in both 2D and advanced 3D cardiac models.

• BFH772 (VEGFR2 inhibitor): Technical Workflow and QC Guidanc

  2026-05-04

  BFH772 is a highly selective VEGFR2 inhibitor designed for precise inhibition of VEGFR2-mediated angiogenesis, particularly in tumor model research. It is not suitable for workflows requiring water solubility or broad-spectrum kinase inhibition, and strict adherence to its solubility and storage profile is necessary for reproducible results.

• Glabridin–Gold(I) Complex Targets TrxR & MAPK to Boost Antit

  2026-05-03

  This study introduces a novel glabridin–gold(I) (6d) complex that synergistically targets thioredoxin reductase (TrxR) and MAPK pathways, enhancing antitumor immune responses while mitigating immunosuppression in the tumor microenvironment. Its dual mechanism represents a promising strategy for improving cancer immunotherapy outcomes, especially in the context of liver cancer.

• Conserved N-ECD Region Regulates GABAA Receptor Surface Traf

  2026-05-02

  This study identifies a highly conserved region in the N-terminal extracellular domain (N-ECD) of GABAA receptor subunits as a critical determinant of receptor trafficking to the cell surface. Its findings clarify how specific mutations disrupt ER processing and chaperone interactions, informing our understanding of inhibitory signaling and its impairment in neurological disease.

• Homoharringtonine Rapidly Clears SARS-CoV-2: Mechanistic Ins

  2026-05-02

  This article examines recent findings demonstrating that homoharringtonine, a well-characterized cytotoxic alkaloid, rapidly inhibits and clears SARS-CoV-2 from the upper respiratory tract, both in animal models and in human patients. The research highlights the compound’s protein synthesis inhibition mechanism and its potential as a first-line defense strategy in future coronavirus outbreaks.

• LY294002: Applied PI3K/Akt/mTOR Inhibition in Cell Signaling

  2026-05-01

  LY294002, a potent reversible PI3K inhibitor, empowers precise dissection of the PI3K/Akt/mTOR axis in cancer biology and immunology. Its proven stability, cell permeability, and dose-responsive performance make it the gold-standard for modulating autophagy, apoptosis, and tumor progression in both in vitro and in vivo assays.

• Myriocin: Serine Palmitoyltransferase Inhibitor for Sphingol

  2026-04-30

  Myriocin, a potent serine palmitoyltransferase inhibitor from APExBIO, unlocks precise control over sphingolipid metabolism for cutting-edge oncology, immunology, and metabolic studies. Learn how to optimize assays, troubleshoot common pitfalls, and leverage recent breakthroughs linking Myriocin to mitochondrial activation and metabolic health.

• Gap19: Selective Connexin 43 Hemichannel Blocker in Research

  2026-04-30

  Gap19 stands out as a selective connexin 43 hemichannel blocker that empowers researchers to dissect neuroglial and immune mechanisms with unparalleled specificity. Its unique selectivity, robust in vitro and in vivo data, and clear protocol guidance position it as a go-to tool for studies of neuroprotection, inflammation, and ATP signaling.

• AM 281 in Precision Neuroprotection: CB1 Antagonism and GLT-

  2026-04-29

  Explore how AM 281, a potent CB1 cannabinoid receptor antagonist, enables targeted modulation of neuronal survival and glutamate homeostasis. This article uniquely bridges mechanistic insight with actionable assay guidance for neuroprotection and memory impairment research.

• Self-Activatable Nanozymes Eradicate Intramacrophage Bacteri

  2026-04-29

  This study presents a self-activatable polymeric nanozyme platform designed to selectively eliminate Fusobacterium nucleatum residing within tumor-associated macrophages in colorectal cancer. By synergistically inducing reactive oxygen species and autophagy, these nanozymes disrupt the immunosuppressive tumor microenvironment, enhancing the efficacy of anti-CD47 immunotherapy.

• KX2-391 Dihydrochloride Suppresses HBV Transcription via Tub

  2026-04-28

  This study identifies KX2-391 dihydrochloride (Tirbanibulin dihydrochloride) as a potent inhibitor of hepatitis B virus (HBV) transcription, acting through disruption of tubulin polymerization rather than Src kinase inhibition. The findings provide a mechanistically distinct approach to HBV suppression, with implications for developing novel antiviral strategies targeting host cell processes.

450 records 19/30 page Previous Next First page 上5页 1617181920 下5页 Last page